-Diagnostic test accuracy studies conducted in sub-Saharan Africa, where one of the index tests was performed using a cross-sectional design -Diagnostic test accuracy studies conducted in sub-Saharan Africa, where two index tests were performed independently in women, using a cross-sectional design -Randomized trial studies with either of the index texts in one arm, when both screening and reference tests were performed at enrollment 2. Literature review strings 2.1. In Medline (PubMed) #1: Africa OR "Africa South of the Sahara" OR "sub-Saharan-Africa" OR "Low resource setting" #2: Angola OR Benin OR Botswana OR "Burkina Faso" OR "Upper Volta" OR Burundi OR Urundi OR Identifying the report as a systematic review, meta-analysis, or both.
T summary Providing a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings.
CTION
Describing the rationale for the review in the context of what is already known.
Providing an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
S
criteria Specifying study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
n sources Describing all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Presenting full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
tion Stating the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
tion Describing method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Listing and defining all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
s in studies
Describing methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level).
easures Stating the principal summary measures (e.g., risk ratio, difference in means).
f results Describing the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
s across Specifying any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
analyses Describing methods of additional analyses (e.g., sensitivity or subgroup analyses, metaregression), if done, indicating which were pre-specified. 
ION
f evidence Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., health care providers, users, and policy makers).
s Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).
s Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. P2  T1  T2  R1  R2  R3  F1  F2  F3  F4  F5  F6 Megevand, 1996 Supplementary figure 2b: Prevalence of disease (CIN2+) in the GSA group, by geographic region GSA: gold standard (colposcopy followed by colposcopy directed biopsies) performed in all women of the study population. CIN2+: cervical intraepithelial neoplasia grade 2 or worse. N: number of patients. VIA: visual inspection with acetic acid. VILI: visual inspection with Lugol's iodine. HPV: Human papillomavirus.
Supplementary figure 3:
Positivity rate of VIA, VILI and HPV testing in the GSA group GSA: gold standard (colposcopy followed by colposcopy directed biopsies) performed in all women of the study population. CIN2+: cervical intraepithelial neoplasia grade 2 or worse. N: overall number of patients. VIA: visual inspection with acetic acid. VILI: visual inspection with Lugol's iodine. HPV: Human papillomavirus.
In the GSP group
Supplementary figure 4a: Prevalence of disease (CIN2+) in the GSP group, by screening test GSP: gold standard (colposcopy followed by directed biopsies) performed in screen positive women and only a portion of screen negative women. CIN2+: cervical intraepithelial neoplasia grade 2 or worse. N: overall number of patients. VIA: visual inspection with acetic acid. HPV: Human papillomavirus.
Supplementary figure 4b: Prevalence of disease (CIN2+) in the GSP group, by geographic region GSP: gold standard (colposcopy followed by directed biopsies) performed in screen positive women and only a portion of screen negative women. CIN2+: cervical intraepithelial neoplasia grade 2 or worse. N: overall number of patients. VIA: visual inspection with acetic acid. HPV: Human papillomavirus.
7.
Forest plots of absolute sensitivity and specificity for CIN2+ detection of VIA and HPV testing in the GSP group Supplementary figure 6: Absolute sensitivity and specificity to detect CIN2+ in the GSP group, by screening test Heterogeneity analysis across studies provided the following Cochran's Q p-values: in VIA studies, p=0.62 and p<0.0001 for sensitivity and specificity, respectively; and in HPV studies, p=0.13 and p=0.08 for sensitivity and specificity, respectively. GSP: gold standard (colposcopy followed by directed biopsies) performed in screen positive women and only a portion of screen negative women. CIN2+: cervical intraepithelial neoplasia grade 2 or worse. N: overall number of patients. VIA: visual inspection with acetic acid. HPV: Human papillomavirus. 
